# Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

> **NCT01283022** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Cervical Ripening
- Induction of Labor

## Interventions

- **DRUG:** MVI 200

## Key facts

- **NCT ID:** NCT01283022
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283022, "Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01283022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*